Why MSK is one of your biggest insurance pressures, and one of the most solvable

Medical inflation is a reality for all employers but it’s one that can be mitigated before any renewals are due by quantifying the exposure to MSK and addressing its impact on employees.

Why MSK is one of your biggest PMI pressures, and one of the most solvable .jpg

When the PMI renewal letter arrives, the response often follows a familiar pattern: brief the broker, benchmark the market, challenge the rate.

It is a reasonable response to an unreasonable situation. What it rarely addresses is why the renewal has risen in the first place.

MSK is now one of the largest and most persistent drivers of UK private medical claims. At the same time, employer-sponsored medical costs continue to rise, with Aon forecasting a 9.8% global increase in medical plan costs in 2026. For many employers, that average conceals a more difficult reality: schemes with higher utilisation, particularly where MSK claims are prominent, can face much sharper renewal pressure.

Insurers are not simply being unreasonable. They are pricing what they see in the claims data. The more useful question is whether that data was inevitable.

Employers can calculate their own exposure using Vitrue Health's MSK cost calculator.

MSK claims do not appear from nowhere

The clinical reality is that many MSK claims follow a predictable pathway. Early discomfort goes unaddressed. Movement confidence reduces. Pain intensifies. Eventually, an employee either goes off sick or seeks private treatment. Both outcomes create cost, but PMI claims make that cost especially visible at renewal.

There is an important tension here. Better benefits access and greater awareness of MSK risk mean more employees are willing to seek help. That is positive. But if the only available pathway is reactive treatment, employers may still see rising utilisation rather than falling risk.

In other words, access alone is not the same as prevention.

Vitrue Health’s actuarial modelling shows how quickly MSK cost can escalate when support happens too late. Moving a case from early pain to serious acute status can increase direct employer spend by more than three times. Allowing that case to become chronic can raise total employer cost by up to six times, once treatment, surgery risk, absence, productivity loss and modified duties are factored in.

For a 2,000-person organisation, Vitrue’s modelling estimates total annual MSK costs across absence, presenteeism, PMI claims and attrition could reach £1 million to £3 million annually.

The insured portion is only one part of the total cost, but it is the part that compounds most visibly when renewal decisions are made.

Prevention is a claims management strategy

This is where benefits professionals have more leverage than many PMI conversations allow.

MSK prevention should not be viewed as a wellbeing initiative sitting separately from medical insurance. Used well, it becomes a claims management strategy. The mechanism is straightforward: identify risk earlier, support employees before pain escalates, and reduce the number of cases reaching the high-cost clinical threshold that generates claims.

An employee who receives timely support before their pain progresses is less likely to become a physiotherapy referral, scan, specialist consultation or surgical authorisation. Just as importantly, they are less likely to appear in next year’s claims data as a high-cost case.

This matters because PMI renewal is retrospective. By the time the letter arrives, the risk has already been priced. The opportunity to influence that renewal sits in the 12 to 18 months before it.

Reading prevention and renewal together

A few practical implications follow for benefits strategy.

First, prevention and PMI budgets need to be read together. If MSK wellbeing spend and PMI renewal sit in separate conversations, the connection insurers make automatically when pricing the scheme may be missed internally.

Second, the population driving future claims is often identifiable earlier than employers realise. Screening data covering pain prevalence, movement risk, work impact and presenteeism can help show which employees are on a trajectory towards more complex care before they reach that point.

Third, timing matters. Benefits decisions made now will either appear in the next renewal cycle as improved utilisation data, or they will not. Waiting until renewal season means negotiating around a risk profile that is already established.

For HR, reward and benefits leaders watching medical inflation stretch budgets, the instinct is often to negotiate harder with insurers. That still matters. But it should not be the whole strategy.

A more durable approach is to reduce what the insurer has to price in the first place. Whether this year’s renewal has already arrived or is still months away, preparation for the next one starts with what is happening to MSK risk inside the workforce right now.

Employers can also start by quantifying their own MSK exposure. Using a dedicated MSK cost calculator helps organisations estimate the potential cost of MSK across absence, productivity, healthcare and workplace support, using their own workforce data or industry benchmarks.